COVID-19 Update: Over 122,000 Nigerians Vaccinatedafter receiving the vaccine, one may develop other diseases unrelated to the vaccination procedure
- Over 122,000 people receive vaccines
- Nigeria has not experienced any serious adverse reactions
- after receiving the vaccine, one may develop other diseases unrelated to the vaccination procedure
- safety of the Oxford-AstraZeneca COVID-19 vaccines has been questioned
According to Faisal Shuaib, Executive Director of the National Primary Health Care Development Agency (NPHCDA), about 122,410 Nigerians have received the Oxford-AstraZeneca COVID-19 vaccine.
Mr Shuaib stated at the Presidential Task Force (PTF) weekly briefing on COVID-19 that Nigeria has not experienced any serious adverse reactions as a result of the administration of the Oxford-AstraZeneca COVID-19 vaccines.
â€œSo far, 122,410 people have been vaccinated with Oxford Astrazeneca vaccine in Nigeria,â€ he said
â€œNo Nigerian so far has developed any known severe side effect, while we have observed that there might be some mild symptoms like pain and swelling at the site of the vaccination, body pains and mild fever.â€
Mr Faisal stated that the agency will continue to work with NAFDAC's "pharmacovigilance team" to monitor vaccine administration and record any adverse reactions.
This, he said, is to reassure Nigerians that the government is being honest and transparent in selecting the vaccine to protect citizens from the virus, which has claimed the lives of over 2,000 people in Nigeria.
According to Boss Mustapha, Chairman of the PTF on COVID-19, the country received 300,000 doses of the Oxford-AstraZeneca COVID-19 vaccines from telecom giant MTN on Sunday.
According to Reuters, Austrian authorities stopped the use of the AstraZeneca vaccines last week while investigating the death of one person and the illness of another after receiving the shots.
Over a dozen countries, including Germany, France, and Italy, announced that they would stop using the vaccine or certain batches of it immediately.
Despite safety concerns, some high-income nations, such as the United Kingdom, and developing countries, such as Nigeria and Ghana, have decided to keep the Oxford-AstraZeneca vaccine on the market.
Representatives of the Nigerian government met with an AstraZeneca team last week, according to the Minister of Health, Osagie Ehanire, and the result was a reassurance of the vaccine's safety and effectiveness against COVID-19.
â€œFull implementation of the COVID-19 vaccination of eligible population has commenced in over 33 states and the FCT while four states (Kogi, Kebbi, Zamfara and Oyo) are yet to commence implementation,â€ he said.
He did, however, say that the vaccination campaign in Kebbi State will begin today.